LIFEVANTAGE CORP Share-based Payment Arrangement, Expense
LIFEVANTAGE CORP (LFVN) reported Share-based Payment Arrangement, Expense of $2.30 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-27
- LIFEVANTAGE CORP share-based payment arrangement, expense for the quarter ending 2026-06-30 was $200.00K, a 86.67% decline year-over-year.
- LIFEVANTAGE CORP share-based payment arrangement, expense for the quarter ending 2026-03-31 was $700.00K, a 53.33% decline year-over-year.
- LIFEVANTAGE CORP share-based payment arrangement, expense for the quarter ending 2025-12-31 was $600.00K, a 64.71% decline year-over-year.
- LIFEVANTAGE CORP share-based payment arrangement, expense for the quarter ending 2025-09-30 was $800.00K, a 11.11% decline year-over-year.
- LIFEVANTAGE CORP share-based payment arrangement, expense for fiscal 2026 was $2.30M, a 59.65% decline from fiscal 2025.
- LIFEVANTAGE CORP share-based payment arrangement, expense for fiscal 2025 was $5.70M.
- LIFEVANTAGE CORP share-based payment arrangement, expense for fiscal 2016 was $1.70M, a 34.62% decline from fiscal 2015.
- LIFEVANTAGE CORP share-based payment arrangement, expense for fiscal 2015 was $2.60M, a 18.18% increase from fiscal 2014.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $900.00K derived: sum of 2 quarters · filed 2026-08-27 | $1.50M derived: sum of 3 quarters · filed 2026-08-27 | $2.30M 10-K · filed 2026-08-27 | |
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-06 | $1.30M derived: sum of 2 quarters · filed 2026-05-06 | $2.10M 10-Q · filed 2026-05-06 | $3.60M derived: sum of 4 quarters · filed 2026-08-27 | |
| 2025-12-31 | $600.00K 10-Q · filed 2026-02-04 | $1.40M 10-Q · filed 2026-02-04 | $2.90M derived: sum of 3 quarters · filed 2026-08-27 | $4.40M derived: sum of 4 quarters · filed 2026-08-27 | |
| 2025-09-30 | $800.00K 10-Q · filed 2025-11-04 | $2.30M derived: sum of 2 quarters · filed 2026-08-27 | $3.80M derived: sum of 3 quarters · filed 2026-08-27 | $5.50M derived: sum of 4 quarters · filed 2026-08-27 | |
| 2025-06-30 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $3.00M derived: sum of 2 quarters · filed 2026-08-27 | $4.70M derived: sum of 3 quarters · filed 2026-08-27 | $5.70M 10-K · filed 2026-08-27 | |
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-06 | $3.20M derived: sum of 2 quarters · filed 2026-05-06 | $4.20M 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | $1.70M 10-Q · filed 2026-02-04 | $2.60M 10-Q · filed 2026-02-04 | |||
| 2024-09-30 | $900.00K 10-Q · filed 2025-11-04 | ||||
| 2024-03-31 | $800.00K 10-Q · filed 2025-05-06 | $1.60M derived: sum of 2 quarters · filed 2025-05-06 | $2.50M 10-Q · filed 2025-05-06 | ||
| 2023-12-31 | $800.00K 10-Q · filed 2025-02-05 | $1.70M 10-Q · filed 2025-02-05 | |||
| 2023-09-30 | $1.00M 10-Q · filed 2024-10-29 | ||||
| 2016-06-30 | $1.70M 10-K · filed 2016-12-12 | ||||
| 2015-06-30 | $2.60M 10-K · filed 2016-12-12 | $1.70M 10-K · filed 2015-09-01 | |||
| 2014-06-30 | $2.20M 10-K · filed 2016-12-12 | $2.61M 10-K · filed 2014-09-10 | |||
| 2013-06-30 | $2.20M 10-K · filed 2015-09-01 | ||||
| 2012-06-30 | $1.20M 10-K · filed 2014-09-10 | ||||
| 2011-06-30 | $700.00K 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |